JP2021520394A5 - - Google Patents

Info

Publication number
JP2021520394A5
JP2021520394A5 JP2020555045A JP2020555045A JP2021520394A5 JP 2021520394 A5 JP2021520394 A5 JP 2021520394A5 JP 2020555045 A JP2020555045 A JP 2020555045A JP 2020555045 A JP2020555045 A JP 2020555045A JP 2021520394 A5 JP2021520394 A5 JP 2021520394A5
Authority
JP
Japan
Prior art keywords
alkyl
group
heterocyclyl
pharmaceutical composition
cycloalkyl
Prior art date
Application number
JP2020555045A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019201752A5 (https=
JP2021520394A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/059341 external-priority patent/WO2019201752A1/en
Publication of JP2021520394A publication Critical patent/JP2021520394A/ja
Publication of JP2021520394A5 publication Critical patent/JP2021520394A5/ja
Publication of JPWO2019201752A5 publication Critical patent/JPWO2019201752A5/ja
Pending legal-status Critical Current

Links

JP2020555045A 2018-04-17 2019-04-11 医薬組成物、処置方法及びその使用 Pending JP2021520394A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18167739.4 2018-04-17
EP18167739 2018-04-17
PCT/EP2019/059341 WO2019201752A1 (en) 2018-04-17 2019-04-11 Pharmaceutical composition, methods for treating and uses thereof

Publications (3)

Publication Number Publication Date
JP2021520394A JP2021520394A (ja) 2021-08-19
JP2021520394A5 true JP2021520394A5 (https=) 2022-04-12
JPWO2019201752A5 JPWO2019201752A5 (https=) 2022-04-12

Family

ID=62017227

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020555045A Pending JP2021520394A (ja) 2018-04-17 2019-04-11 医薬組成物、処置方法及びその使用

Country Status (6)

Country Link
US (1) US20210113561A1 (https=)
EP (1) EP3781166A1 (https=)
JP (1) JP2021520394A (https=)
CN (1) CN111989103A (https=)
AU (1) AU2019254371A1 (https=)
WO (1) WO2019201752A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3873600T5 (da) 2018-10-29 2024-03-18 Boehringer Ingelheim Int Pyridinylsulfonamidderivater, farmaceutiske sammensætninger og anvendelser deraf
US12213970B2 (en) 2018-10-29 2025-02-04 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
CN113893256A (zh) * 2020-07-06 2022-01-07 诺未科技(北京)有限公司 化合物或其可药用盐、二聚体或三聚体在制备治疗癌症的药物中的应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE264337T1 (de) 1999-08-31 2004-04-15 Kissei Pharmaceutical Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
AU2002223127A1 (en) 2000-11-30 2002-06-11 Kissei Pharmaceutical Co., Ltd. Intellectual Property Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
PL209375B1 (pl) 2000-12-28 2011-08-31 Kissei Pharmaceutical Pochodne glukopiranozyloksypirazolu, kompozycja farmaceutyczna zawierająca takie pochodne i zastosowanie tych pochodnych do wytwarzania kompozycji farmaceutycznej
JP4490109B2 (ja) 2002-03-22 2010-06-23 キッセイ薬品工業株式会社 グルコピラノシルオキシベンジルベンゼン誘導体の結晶
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
ES2567571T3 (es) 2003-03-14 2016-04-25 Astellas Pharma Inc. Derivados de C-glucósido y sales de los mismos
LT2896397T (lt) 2003-08-01 2017-11-27 Mitsubishi Tanabe Pharma Corporation Nauji junginiai, turintys inhibitorinį aktyvumą prieš nuo natrio priklausomą gliukozės transporterį
ATE557013T1 (de) 2004-03-16 2012-05-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2007093610A1 (en) 2006-02-15 2007-08-23 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
JP5230613B2 (ja) 2006-05-23 2013-07-10 テラコス・インコーポレイテッド グルコース輸送体阻害剤およびその使用方法
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
WO2008109591A1 (en) 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
AR065809A1 (es) 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
AU2008279424B2 (en) 2007-07-26 2013-06-13 Lexicon Pharmaceuticals, Inc. Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
MX2010002695A (es) 2007-09-10 2010-04-01 Janssen Pharmaceutica Nv Proceso para la preparacion de compuestos utiles como inhibidores de transportador de glucosa dependiente de sodio (sglt).
TW201011043A (en) 2008-06-20 2010-03-16 Chugai Pharmaceutical Co Ltd Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
TWI472521B (zh) 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc (2s,3r,4r,5s,6r)-2-(4-氯-3-(4-乙氧苄基)苯基)-6-(甲硫)四氫-2h-哌喃-3,4,5-三醇的固體形態與其使用方法
MY155418A (en) 2008-08-28 2015-10-15 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
KR101921934B1 (ko) 2009-02-13 2018-11-26 베링거 인겔하임 인터내셔날 게엠베하 글루코피라노실 디페닐메탄 유도체를 포함하는 약제학적 조성물, 이들의 약제학적 용량형, 이들의 제조방법 및 환자에서의 개선된 당 조절을 위한 이들의 용도
BRPI1008560B1 (pt) * 2009-02-13 2021-08-31 Boehringer Ingelheim International Gmbh Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos
AP2011005795A0 (en) * 2009-02-13 2011-08-31 Boehringer Ingelheim Int SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia.
EP2419097B1 (en) 2009-04-16 2013-09-25 Taisho Pharmaceutical Co., Ltd. Pharmaceutical composition comprising (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol and metformin and uses thereof in the treatment of diabetes
AU2010303123B2 (en) 2009-09-30 2014-02-27 Boehringer Ingelheim International Gmbh Method for the preparation of a crystalline form of 1-chloro-4- (Beta-D-glucopyranos-1-yl)-2-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)benzene
JP5758900B2 (ja) 2009-09-30 2015-08-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換ベンジルベンゼン誘導体の調製方法
WO2014123749A1 (en) * 2013-01-30 2014-08-14 Board Of Regents Of The University Of Nebraska Compositions and methods for treating complications associated with diabetes
JP2018501276A (ja) * 2015-01-09 2018-01-18 ギリアド アポロ, エルエルシー 非アルコール性脂肪肝疾患の処置のためのacc阻害剤併用療法
ES2844926T3 (es) * 2016-05-12 2021-07-23 Boehringer Ingelheim Int Derivados de piridinilo, composiciones farmacéuticas y usos de los mismos como inhibidores de AOC3

Similar Documents

Publication Publication Date Title
JP2019531320A5 (https=)
US11524930B2 (en) Substituted aromatic compounds and related method for the treatment of fibrosis
JP6022657B2 (ja) キナーゼカスケードを調節するための組成物および方法
JP5564251B2 (ja) キナーゼカスケードを調節するためのビアリール組成物および方法
JP2021520394A5 (https=)
JP4974463B2 (ja) インダン酢酸誘導体ならびに製薬学的薬剤としてのそれらの使用、中間体及び製造方法
JP2005162612A (ja) アシルスルホンアミド誘導体
JP2019069941A (ja) スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
JP5679811B2 (ja) キナーゼカスケードを調節するための組成物の調製のための方法ならびにその使用方法
CN104144920A (zh) 作为gpr促效剂的苯基烷酸衍生物
JP2021504423A5 (https=)
WO2003059871A1 (en) N-alkylsulfonyl-substituted amide derivatives
JP7412004B2 (ja) 抗菌剤化合物
TW200306812A (en) Benzofuran derivatives
JP2019131544A5 (https=)
JP2005119987A (ja) アシルスルホンアミド誘導体
CN103304500B (zh) 新型抗糖尿病化合物、其制备方法和用途
JP6908805B2 (ja) Cnsおよび他の障害の処置のためのベンゾフラン誘導体
WO1990005132A1 (fr) Derives d'allylamine substitues, procede de preparation et utilisation
JPWO2019201752A5 (https=)
JPWO2022071578A5 (https=)
JP4443033B2 (ja) ポリヒドロキシブチルピラジン類、それらの製造法およびそれらを含有する医薬
JPWO2023152698A5 (https=)
KR20200016793A (ko) 티아민 유도체를 포함하는 혈관 또는 판막 석회화의 예방 또는 치료용 조성물
JP2021134211A5 (https=)